Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Inmaculada Gallego-Jimenez"'
Autor:
Alfredo Carrato, Roberto Pazo-Cid, Teresa Macarulla, Javier Gallego, Paula Jiménez-Fonseca, Fernando Rivera, Maria Teresa Cano, Mercedes Rodríguez Garrote, Carles Pericay, Inmaculada Diaz, Laura Layos, Begoña Graña, Vega Iranzo, Inmaculada Gallego-Jimenez, Rocio Garcia-Carbonero, Maria Alvarez Alejandro, Inmaculada Ruiz de Mena, CARMEN GUILLEN PONCE, Enrique Aranda
Publikováno v:
Journal of Clinical Oncology. 40:4022-4022
4022 Background: Sequential treatment with nab-paclitaxel, gemcitabine followed by oxaliplatin, leucovorin and 5-fluorouracil ( nab-P/Gem-mFOLFOX) have shown a good safety profile and clinical activity in metastatic pancreatic ductal adenocarcinoma (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e8e65477ca8dd9a9874317eb60c4570
https://doi.org/10.1200/jco.2022.40.16_suppl.4022
https://doi.org/10.1200/jco.2022.40.16_suppl.4022
Autor:
Inmaculada Gallego Jimenez, Jose Luis Garcia De Veas, Clara Garcia Grove, Fernando Leopoldo Tallafigo, M. Luisa Limon
Publikováno v:
Journal of Clinical Oncology. 40:e15530-e15530
e15530 Background: Recently the European Medicines Agency (EMA) and the Spanish Medicines Agency (AEMPS) recommend performing a phenotypic and/or genotypic test before starting treatment with fluoropyrimidines The objective of this work has been to a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c9467e4f64e29854d29fc7eb4ef34e2
https://doi.org/10.1200/jco.2022.40.16_suppl.e15530
https://doi.org/10.1200/jco.2022.40.16_suppl.e15530
Publikováno v:
Journal of Clinical Oncology. 32:e14631-e14631
e14631 Background: The variability in survival of colorectal cancer is defined by different parameters. Our goal is to assess whether the simplified model group GERCOR forecast predicts mortality i...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66883d01c0ecfec6ca6b378b4f9e957e
https://doi.org/10.1200/jco.2014.32.15_suppl.e14631
https://doi.org/10.1200/jco.2014.32.15_suppl.e14631
Autor:
Inmaculada Gallego Jimenez, Maria Rodriguez de la Borbolla, Jose Fuentes Pradera, Amelia Lopez Ladron, Javier Salvador Bofill, Eva Fernandez Parra, David Morales Pancorbo, Reyes Bernabe Caro
Publikováno v:
Journal of Clinical Oncology. 32:665-665
665 Background: Bevacizumab, a humanized antibody against the molecular target endotelial growth factor VEGF-A, has incorporated to the standard of care of metastatic colon-rectal cancer (mCRC). A recent study has suggested that the left colon locali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6b7734c2c43f510a6128ab8de6cabfe
https://doi.org/10.1200/jco.2014.32.3_suppl.665
https://doi.org/10.1200/jco.2014.32.3_suppl.665
Autor:
J. Bayo, Inmaculada Gallego Jimenez, David Morales Pancorbo, Jose Fuentes Pradera, Javier Salvador, Eva Fernandez Parra, R. Bernabé, Maria Rodriguez de la Borbolla, Amelia Lopez Ladron
Publikováno v:
Journal of Clinical Oncology. 30:e11075-e11075
e11075 Background: Overexpression HER 2 + + + is a distinct group within the breast cancer with different treatments in both the adjuvant and advanced setting. However, from the clinical point of view, there are significant differences within this gr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bfba85ee650a4746b888421d0029641
https://doi.org/10.1200/jco.2012.30.15_suppl.e11075
https://doi.org/10.1200/jco.2012.30.15_suppl.e11075
Autor:
Inmaculada, Gallego Jimenez, Susana, Rico Gala, Amelia, López-Ladrón, Fernández-Parra Eva, M., David, Morales Pancorbo, Javier, Salvador Bofill Francisco
Publikováno v:
In Annals of Oncology June 2014 25 Supplement 2:ii103-ii103